[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625390":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":35,"responsibleParty":49,"collaborators":51,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":10,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":10,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":10,"overallStatus":74,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Baylor Research Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Pregnant Individuals",null,"Individuals who had a uterus transplant that are using tacrolimus during pregnancy.",[13],"Biological: Modeling of unbound and whole blood tacrolimus in pregnant uterus transplant recipients",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"BIOLOGICAL","Modeling of unbound and whole blood tacrolimus in pregnant uterus transplant recipients","Develop an estimating equation to correct tacrolimus whole blood concentrations given the known increase in the unbound tacrolimus concentration in pregnant patients to obtain a more accurate picture of active tacrolimus exposure (unbound drug) in pregnant uterus transplant recipients.",[9],[21],{"name":22,"affiliation":23,"role":24},"Nicole Wilson, Pharmacist","Baylor Scott and White Health","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Ashley McAllister","CONTACT","214-820-1710","ashley.mcallister@bswhealth.org",{"name":32,"role":28,"phone":33,"phoneExt":10,"email":34},"Taryn Kruse","214-820-1767","taryn.kruse@bswhealth.org",[36],{"facility":37,"status":10,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":10},"Baylor University Center of Dallas","Dallas","Texas","75246","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-96.80667,32.78306,{"lat":47,"lon":46},{"type":50,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[52,54],{"name":53,"class":6},"Children's Hospital Medical Center, Cincinnati",{"name":55,"class":6},"University of Washington","100625390","tacrolimus-in-pregnancy-100625390",false,"NCT07422012","Tacrolimus in Pregnancy","Optimization of Tacrolimus Management During Pregnancy: Modeling of Unbound and Whole Blood Tacrolimus in Pregnant Uterus Transplant Recipients","Inclusion Criteria:\n\n* Uterus transplant recipient\n* 18 to 50 years of age\n* receiving tacrolimus for immunosuppression.\n\nExclusion Criteria:\n\n* Individuals who have not had a uterine transplant\n* individuals over 50 years old","FEMALE","18 Years","50 Years",{"count":67,"type":68},55,"ESTIMATED","OBSERVATIONAL","To create a formula that adjusts tacrolimus blood levels. This is needed because pregnant patients have higher levels of unbound tacrolimus. The adjusted formula will give a more accurate measure of the active drug in pregnant uterus transplant patients.",[72,73],"Unbound Tacrolimus in Pregnant Uterus Transplant Recipients","Whole Blood Tacrolimus in Pregnant Uterus Transplant Recipients","NOT_YET_RECRUITING","2026-04-24",{"date":77,"type":78},"2026-04-28","ACTUAL",{"date":80,"type":68},"2026-05-31",{"date":82,"type":68},"2028-03",{"name":5,"class":6},1]